Prescribing Opioids

This research report from NIDA discusses sex and gender influences in substance use, highlighting the unique needs of women when addressing substance use. disorder treatment

These reports and detailed tables present estimates from the 2019 National Survey on Drug Use and Health (NSDUH), specifically pertaining to substance use among women.

This is a toolkit on addressing pain in patients with opioid use disorder (OUD) and managing medication for addiction treatment (MAT) during the perioperative/postpartum period.

This FDA page provides an index of over 400 FDA approved drugs and their descriptions. Note that it does not include all FDA approved drugs, but shares other resources to find more information on drugs not included on the list.

This toolkit is tailored specifically to the unique needs of multidisciplinary substance use disorder (SUD) providers and programs serving perinatal individuals. It is meant to be a quick reference resource about mental health and SUD specific to perinatal individuals.

This toolkit provides tools to both providers and patients for the assessment and management of perinatal mood and anxiety disorders, as well as substance use disorders (SUD).

This document summarizes a discussion from a workshop where experts examined the evidence for candidate endpoints and study design strategies for clinical trials of stimulant use disorder treatments.

This was a virtual public workshop to discuss a practical research agenda toward treatment development for stimulant use disorder. Meeting participants responded to a proposed practical research agenda that focuses on innovation in clinical trial design and candidate endpoints for the evaluation of potential treatments for stimulant use disorder.

This document summarizes the discussion from the meeting of clinicians and researchers who are knowledgeable about screening for fentanyl and other drugs, primarily in health care settings. The focus of the meeting was to understand clinician/researcher perspectives about clinical fentanyl testing and distribution of fentanyl test strips (FTS) to patients and discuss next steps for technology development, research, and practice.

This guideline updates the state of the science on pain research, care, and education with a particular focus on informing the Food and Drug Administration's (FDA's) development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.